ZOM
(NYSE)
1.01
-0.0750   (-6.94%)
 
Volume (24h) Market Cap. Day Range 52w Range
68.62M 569.69M 0.99 - 1.09 0.0628 - 1.48
Jan-18-21 06:15AM Zomedica CEO Issues Shareholder Letter as TRUFORMA™ Nears CommercializationGlobeNewswire
Jan-15-21 06:23AM Jeremy Grantham’s Bubble Forecast Is an Outlier. Is He Right?Barrons.com
Jan-12-21 05:53AM Penny stock Zomedica jumps 250% after someone paid Netflix star Carole Baskin $299 for a mentionYahoo Finance
Jan-04-21 06:10AM Zomedica Appoints Robert Cohen CEO as Company Nears Commercialization of TRUFORMA™GlobeNewswire
Dec-15-20 08:53AM Zomedica to Remain Domiciled in CanadaGlobeNewswire
Dec-07-20 06:01AM Zomedica Completes Internal “Launch Team” for Upcoming TRUFORMA™ CommercializationGlobeNewswire
Nov-28-20 08:50AM Is Zomedica Corp. (ZOM) A Good Stock To Buy Now?Insider Monkey
Nov-18-20 12:38PM Is Zomedica Stock a Buy Right Now? This Analyst Says ‘Yes’TipRanks
Nov-13-20 06:00AM Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™GlobeNewswire
Nov-12-20 06:30AM Zomedica Announces Third Quarter 2020 Financial ResultsGlobeNewswire
Oct-26-20 09:25AM Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Special Virtual-Only MeetingGlobeNewswire
Oct-02-20 05:05AM Zomedica Announces Name ChangeGlobeNewswire
Sep-25-20 11:00AM Zomedica Announces Shareholder Meeting Voting ResultsGlobeNewswire
Sep-14-20 05:44AM Zomedica Announces Letter to Shareholders in Connection With Annual and Special Virtual-Only MeetingGlobeNewswire
Sep-10-20 06:55AM Zomedica Announces Presentation at Upcoming H.C. Wainwright Virtual Global Investment ConferenceGlobeNewswire
Sep-08-20 06:55AM Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™GlobeNewswire
Aug-27-20 06:55AM Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only MeetingGlobeNewswire
Aug-10-20 04:15AM Zomedica Announces Second Quarter 2020 Financial ResultsGlobeNewswire
Aug-07-20 06:55AM Zomedica Adds Two New Directors To Board Annual Meeting Materials AvailabilityGlobeNewswire
Aug-03-20 06:55AM Zomedica Announces Management ChangeGlobeNewswire
Jul-21-20 04:01AM Successful Remote Installation of TRUFORMA™GlobeNewswire
Jul-07-20 04:01AM Zomedica Pharmaceuticals Corp. Closes $30 Million Public OfferingGlobeNewswire
Jul-01-20 10:30AM Zomedica Pharmaceuticals Corp. Announces $30 Million Public OfferingGlobeNewswire
04:04AM Zomedica Pharmaceuticals Corp. Announces Proposed Public OfferingGlobeNewswire
Jun-25-20 09:26AM PCG Research Announces Publication of Update Report Covering Zomedica Pharmaceuticals Corp.Newsfile
Jun-16-20 06:05AM Zomedica Appoints New Interim CEO to Lead Organization Through Inaugural Product LaunchGlobeNewswire
May-29-20 04:05AM Zomedica Pharmaceuticals Corp. Closes $20 Million Public OfferingGlobeNewswire
May-26-20 10:16AM Zomedica Pharmaceuticals Corp. Announces $20 Million Public OfferingGlobeNewswire
May-20-20 04:05AM Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic PlatformGlobeNewswire
May-11-20 04:20AM Zomedica Announces First Quarter 2020 Financial ResultsGlobeNewswire
Apr-21-20 06:55AM Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4GlobeNewswire
Apr-13-20 07:15AM Zomedica Provides Corporate UpdateGlobeNewswire
Apr-07-20 11:32AM Zomedica Pharmaceuticals Corp. Announces Pricing of $4.0 Million Public OfferingGlobeNewswire
04:01AM Zomedica Pharmaceuticals Corp. Announces Public OfferingGlobeNewswire
Feb-26-20 05:25AM Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial ResultsGlobeNewswire
Feb-14-20 04:15AM Zomedica Announces Completion of $2.5 Million Registered Direct OfferingGlobeNewswire
Feb-12-20 08:43AM Zomedica Announces $2.5 Million Registered Direct OfferingGlobeNewswire
Feb-11-20 06:55AM Zomedica Files U.S. Patent Application for Fecal Parasite DetectionGlobeNewswire
Jan-30-20 06:55AM Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020GlobeNewswire
Jan-23-20 06:55AM Zomedica to Focus on TRUFORMA™ CommercializationGlobeNewswire
Jan-20-20 06:55AM Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy PlatformGlobeNewswire
Dec-23-19 04:00AM Hedge Funds Have Never Been This Bullish On Zomedica Pharmaceuticals Corp. (ZOM)Insider Monkey
Dec-03-19 06:55AM Zomedica Announces Management ChangesGlobeNewswire
Nov-13-19 06:55AM Zomedica Expands ZM-006 Pilot Efficacy StudyGlobeNewswire
Nov-12-19 04:53AM Zomedica Announces Third Quarter 2019 Financial ResultsGlobeNewswire
Nov-05-19 04:15AM Zomedica Announces 2019 Annual Meeting ResultsGlobeNewswire
Oct-31-19 06:55AM Zomedica Commences Final TRUFORMA™ Diagnostic Verification StudyGlobeNewswire
Oct-03-19 11:27AM CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics MarketNewsfile
Oct-01-19 09:17AM Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics MarketNewsfile
Sep-18-19 01:39AM Do Insiders Own Shares In Zomedica Pharmaceuticals Corp. (CVE:ZOM)?Simply Wall St.
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Cap:    |  Volume (24h):